Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
出版年份 2022 全文链接
标题
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
作者
关键词
-
出版物
OncoImmunology
Volume 11, Issue 1, Pages -
出版商
Informa UK Limited
发表日期
2022-02-01
DOI
10.1080/2162402x.2022.2033528
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
- (2021) Nisha B. Nagarsheth et al. NATURE MEDICINE
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function
- (2020) Frederike A. Hartl et al. NATURE IMMUNOLOGY
- Inefficient CAR-proximal signaling blunts antigen sensitivity
- (2020) Venugopal Gudipati et al. NATURE IMMUNOLOGY
- Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic
- (2019) Laura T. Morton et al. MOLECULAR THERAPY
- Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function
- (2019) Sharyn Thomas et al. Nature Communications
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
- (2018) A. J. Davenport et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Strategies to Address Chimeric Antigen Receptor Tonic Signaling
- (2018) Adam Ajina et al. MOLECULAR CANCER THERAPEUTICS
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains
- (2017) Daniel T. Harris et al. JOURNAL OF IMMUNOLOGY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
- (2017) Diogo Gomes-Silva et al. Cell Reports
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies
- (2016) Lorenz Jahn et al. Oncotarget
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
- (2016) Vita Golubovskaya et al. Cancers
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
- (2015) Kathrin Schumann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD
- (2015) A. Kunkele et al. Cancer Immunology Research
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treating cancer with genetically engineered T cells
- (2011) Tristen S. Park et al. TRENDS IN BIOTECHNOLOGY
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- T-cell receptor gene transfer for the treatment of leukemia and other tumors
- (2010) M. H.M. Heemskerk HAEMATOLOGICA
- Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors
- (2009) Bart A. Nijmeijer et al. EXPERIMENTAL HEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started